Kronos Bio, Inc.
NASDAQ Global SelectTotal Valuation
Kronos Bio, Inc. carries a market capitalization of 53.65M, placing it among publicly traded companies globally. Its enterprise value stands at -25.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 53.65M |
| Enterprise Value | -25.82M |
Share Statistics
Kronos Bio, Inc. currently has 60.97M shares outstanding.
| Shares Outstanding | 60.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 5.42, and the price-to-book ratio stands at -0.08.
| PE Ratio | N/A |
| PS Ratio | 5.42 |
| PB Ratio | -0.08 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | -0.92 |
| P/OCF Ratio | -0.92 |
Financial Position
Kronos Bio, Inc. maintains a current ratio of 12.93, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.93 |
| Quick Ratio | 12.66 |
| Debt / Equity | 30.18 |
| Debt / EBITDA | -0.49 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -44.30 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Kronos Bio, Inc.'s stock has declined approximately -29.6% over the past 52 weeks. The 50-day moving average sits at 0.80, while the 200-day moving average is 0.90.
| Beta (5Y) | N/A |
| 52-Week Price Change | -29.6% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 0.90 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kronos Bio, Inc. generated 9.19M in revenue and converted that into -64.48M in net income, yielding earnings per share of -1.07. EBITDA reached -49.14M, while operating income came in at -50.60M.
| Revenue | 9.19M |
| Gross Profit | N/A |
| Operating Income | -50.60M |
| Pretax Income | -64.48M |
| Net Income | -64.48M |
| EBITDA | -49.14M |
| EBIT | -50.60M |
| Earnings Per Share (EPS) | -1.07 |
Balance Sheet
Kronos Bio, Inc. holds 99.73M in cash and equivalents against 24.09M in total debt, resulting in a net debt position of -91.58M. Total book value stands at -603.24M, with working capital of 93.99M providing operational flexibility.
| Cash & Cash Equivalents | 99.73M |
| Total Debt | 24.09M |
| Net Debt | -91.58M |
| Equity (Book Value) | -603.24M |
| Book Value Per Share | -9.99 |
| Working Capital | 93.99M |
Cash Flow
Kronos Bio, Inc. produced -54.38M in operating cash flow over the past twelve months. After subtracting 3,000.00 in capital expenditures, free cash flow totaled -54.37M - equivalent to -0.90 per share.
| Operating Cash Flow | -54.38M |
| Capital Expenditures | 3,000.00 |
| Free Cash Flow | -54.37M |
| FCF Per Share | -0.90 |
Margins
Kronos Bio, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -550.46 and net profit margin of -701.53 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -550.46 |
| Pretax Margin | -701.53 |
| Profit Margin | -701.53 |
| EBITDA Margin | -534.56 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.49 |
| FCF Yield | -109.15 |
Scores
Kronos Bio, Inc. posts an Altman Z-Score of -7.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.17 |